1. Home
  2. VERX vs SNDX Comparison

VERX vs SNDX Comparison

Compare VERX & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Inc.

VERX

Vertex Inc.

HOLD

Current Price

$13.15

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$19.23

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERX
SNDX
Founded
1978
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
VERX
SNDX
Price
$13.15
$19.23
Analyst Decision
Buy
Strong Buy
Analyst Count
12
13
Target Price
$24.25
$38.69
AVG Volume (30 Days)
999.6K
1.3M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
$748,444,000.00
$172,352,000.00
Revenue This Year
$12.78
$107.19
Revenue Next Year
$11.61
$41.88
P/E Ratio
$302.25
N/A
Revenue Growth
12.25
627.84
52 Week Low
$10.59
$8.59
52 Week High
$42.44
$25.59

Technical Indicators

Market Signals
Indicator
VERX
SNDX
Relative Strength Index (RSI) 57.42 29.55
Support Level $11.91 $14.91
Resistance Level $13.73 $22.33
Average True Range (ATR) 0.65 1.05
MACD 0.16 -0.44
Stochastic Oscillator 76.41 3.88

Price Performance

Historical Comparison
VERX
SNDX

About VERX Vertex Inc.

Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: